| Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a … M Shrotri, M Krutikov, T Palmer, R Giddings, B Azmi, S Subbarao, C Fuller, ... The Lancet Infectious Diseases 21 (11), 1529-1538, 2021 | 215 | 2021 |
| Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection AC Dowell, MS Butler, E Jinks, G Tut, T Lancaster, P Sylla, J Begum, ... Nature immunology 23 (1), 40-49, 2022 | 185 | 2022 |
| Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study … M Krutikov, T Palmer, G Tut, C Fuller, B Azmi, R Giddings, M Shrotri, ... The Lancet Healthy Longevity 3 (1), e13-e21, 2022 | 108 | 2022 |
| Measuring microtubule dynamics AJ Zwetsloot, G Tut, A Straube Essays in biochemistry 62 (6), 725-735, 2018 | 89 | 2018 |
| Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study M Krutikov, T Palmer, G Tut, C Fuller, M Shrotri, H Williams, D Davies, ... The Lancet Healthy Longevity 2 (6), e362-e370, 2021 | 74 | 2021 |
| Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an … G Tut, T Lancaster, M Krutikov, P Sylla, D Bone, N Kaur, E Spalkova, ... The Lancet Healthy Longevity 2 (9), e544-e553, 2021 | 55 | 2021 |
| Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study M Krutikov, O Stirrup, H Nacer-Laidi, B Azmi, C Fuller, G Tut, T Palmer, ... The Lancet Healthy longevity 3 (5), e347-e355, 2022 | 50 | 2022 |
| Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5–6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis H Parry, R Bruton, G Tut, M Ali, C Stephens, D Greenwood, S Faustini, ... The Lancet Healthy Longevity 2 (9), e554-e560, 2021 | 46 | 2021 |
| Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a … M Shrotri, M Krutikov, H Nacer-Laidi, B Azmi, T Palmer, R Giddings, ... The Lancet Healthy Longevity 3 (7), e470-e480, 2022 | 41 | 2022 |
| Single vaccination with BNT162b2 or ChAdOx1 in older people induces equivalent antibody generation but enhanced cellular responses after ChAdOx1 HM Parry, R Bruton, G Tut, M Ali, C Stephens, S Faustini, A Huissoon, ... | 28 | 2021 |
| mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P. 1 Brazilian variant H Parry, G Tut, R Bruton, S Faustini, C Stephens, P Saunders, C Bentley, ... Elife 10, e69375, 2021 | 27 | 2021 |
| Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study G Tut, T Lancaster, P Sylla, MS Butler, N Kaur, E Spalkova, C Bentley, ... The Lancet Healthy Longevity 3 (7), e461-e469, 2022 | 25 | 2022 |
| COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia H Parry, R Bruton, T Roberts, G McIlroy, S Damery, P Sylla, AC Dowell, ... Cancer Cell 40 (6), 584-586, 2022 | 23 | 2022 |
| BNT162b2 vaccination in people over 80 years of age induces strong humoral immune responses with cross neutralisation of P. 1 Brazilian variant HM Parry, G Tut, S Faustini, C Stephens, P Saunders, C Bentley, ... | 22 | 2021 |
| Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes G Tut, T Lancaster, M Krutikov, P Sylla, D Bone, E Spalkova, C Bentley, ... Nature Aging 3 (1), 93-104, 2023 | 17 | 2023 |
| Children develop strong and sustained cross-reactive immune responses against spike protein following SARS-CoV-2 infection AC Dowell, MS Butler, E Jinks, G Tut, T Lancaster, P Sylla, J Begum, ... | 11 | 2021 |
| Clinical effectiveness of SARS-CoV-2 booster vaccine against Omicron infection in residents and staff of Long-Term Care Facilities: a prospective cohort study (VIVALDI) O Stirrup, M Shrotri, NL Adams, M Krutikov, H Nacer-Laidi, B Azmi, ... Open Forum Infectious Diseases 10 (1), ofac694, 2023 | 10 | 2023 |
| Changes in COVID-19 outbreak severity and duration in long-term care facilities following vaccine introduction, England, November 2020 to June 2021 R Giddings, M Krutikov, T Palmer, C Fuller, B Azmi, M Shrotri, ... Eurosurveillance 26 (46), 2100995, 2021 | 10 | 2021 |
| COVID-19 Genomics UK consortium. Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study M Krutikov, O Stirrup, H Nacer-Laidi, B Azmi, C Fuller, G Tut, T Palmer, ... Lancet Healthy Longev 3 (5), e347-e355, 2022 | 8 | 2022 |
| Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection G Tut, T Lancaster, MS Butler, P Sylla, E Spalkova, D Bone, N Kaur, ... Nature Aging 2 (6), 536-547, 2022 | 7 | 2022 |
